All In MedTech

FDA Clearance Tracker · P010012-S526

CONTAK CD,EASYTRAK, LIVIAN, COGNIS AND ACUITY SPIRIAL AUTOMATIC IMPLANTABLE CARDIAC RESYNCHRONIZATION THERAPY DEFIBRILLL

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Nov 12, 2020 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Nov 12, 2020

Approved

Time to decision

27 days

Received Oct 16, 2020. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P010012-S526
Device name
CONTAK CD,EASYTRAK, LIVIAN, COGNIS AND ACUITY SPIRIAL AUTOMATIC IMPLANTABLE CARDIAC RESYNCHRONIZATION THERAPY DEFIBRILLL
Applicant location
St Paul, MN
Received
Oct 16, 2020
Decided
Nov 12, 2020
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Postapproval Study Protocol
Original approval
P010012

Device type

Device class
Class III

Every decision under product code NIK

FDA's approval statement

As written in FDA's record.

Approval to suspend enrollment in the MANAGE-HF Phase II Post-Approval Study for six (6) months due to COVID-19.

Source documents

Other decisions for Boston Scientific Corp

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.